Prilosec Summary Judgment Narrows Scope Of Patent Infringement Case
Executive Summary
AstraZeneca's delayed-release formulation patents for its gastric ulcer drug Prilosec will be the focus of patent infringement litigation after a federal court dismissed as invalid one of the company's "method of treatment" patents.
You may also be interested in...
Protonix, Nexium Growing Share, Wyeth Says; No Prilosec Generic In '01
Wyeth-Ayerst's Protonix and AstraZeneca's Nexium are the only proton pump inhibitors growing market share, Wyeth Pharmaceuticals President Bernard Poussot said during an Oct. 23 conference call.
Protonix, Nexium Growing Share, Wyeth Says; No Prilosec Generic In '01
Wyeth-Ayerst's Protonix and AstraZeneca's Nexium are the only proton pump inhibitors growing market share, Wyeth Pharmaceuticals President Bernard Poussot said during an Oct. 23 conference call.
AstraZeneca Mulls AaiPharma Omeprazole Patent; Will Not List Two Others
AstraZeneca is expected to make a decision on whether to list an aaiPharma patent covering omeprazole in the "Orange Book" by the end of the month.